<DOC>
	<DOCNO>NCT00361023</DOCNO>
	<brief_summary>Angiotensin type-1 receptor ( AT1R ) blocker ( ARBs ) recognize recently regulator glucose lipid metabolism adipocytes adipose tissue.Moreover telmisartan irbesartan recognize recently regulator glucose metabolism . For ARB losartan , result controversial . To confirm effect glucose metabolism , design perform prospective , randomize control study subject type 2 diabetes nephropathy .</brief_summary>
	<brief_title>Effects Losartan Insulin Sensitivity Secretion Type 2 Diabetes Nephropathy</brief_title>
	<detailed_description>Angiotensin II ( AngII ) , main effector peptide rennin-angiotensin system ( RAS ) , implicate development vascular , cardiac , renal pathology . Several line evidence suggest AngII impair insulin sensitivity.Angiotensin type-1 receptor ( AT1R ) blocker ( ARBs ) recognize recently regulator glucose lipid metabolism adipocytes adipose tissue . Recent clinical trial suggest blockade RAS , either inhibit angiotensin-converting enzyme ( ACE ) block AT1R , may substantially low risk type 2 diabetes . In Heart Outcomes Prevention Evaluation ( HOPE ) trial , 34 % reduction relative risk development type 2 diabetes . Similarly , Intervention For Endpoint Reduction Hypertension study ( LIFE ) , incidence type 2 diabetes reduce 25 % losartan group compare antihypertensive therapy . Previous study demonstrate AT1R blockade improve insulin sensitivity animal model insulin resistance . The underlie mechanism insulin sensitize anti-diabetic effect ARBs incompletely clear . The nuclear hormone receptor peroxisome proliferator activate receptor- ( PPAR-γ ) play important role regulation insulin sensitivity . Several study show ARBs telmisartan irbesartan potently induce PPAR-γ activity , promote PPAR-γ-dependent differentiation adipocytes . However , ARBs PPAR-γ activate property . In vitro study show significant difference among PPAR-γ activate ARBs likely cause physicochemical property , high lipophilicity require obtain sufficiently high penetration rate bind intracellular PPAR-γ . Losartan high concentration could activate PPAR-γ behave like partial PPAR-γ agonist . Nevertheless result losartan insulin sensitivity remain controversial . To elucidate underlying effect losartan insulin sensitivity , investigated effect losartan insulin sensitivity secretion patient type 2 diabetes nephropathy .</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Kidney Diseases</mesh_term>
	<mesh_term>Hypersensitivity</mesh_term>
	<mesh_term>Insulin Resistance</mesh_term>
	<mesh_term>Diabetic Nephropathies</mesh_term>
	<mesh_term>Insulin</mesh_term>
	<mesh_term>Losartan</mesh_term>
	<criteria>Fasting plasma glucose ( FPG ) level 3.39.0mmol/L 2h plasma glucose level 7.513 mmol/L Body mass index ( BMI ) 22 kg/m2 Two occasion ratio urinary albumin urinary creatinine≥300 24 hour urinary protein concentration ＞150mg . Informed consent Type1 diabetes nondiabetic renal disease</criteria>
	<gender>All</gender>
	<minimum_age>17 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2006</verification_date>
	<keyword>Angiotensin type 1 receptor blocker ( ARB )</keyword>
	<keyword>losartan</keyword>
	<keyword>type 2 diabetes</keyword>
	<keyword>insulin sensitivity secretion</keyword>
	<keyword>glucose metabolism</keyword>
</DOC>